Navigation Links
Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance

REDWOOD CITY, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the fourth quarter and year ended December 31, 2008.

Total revenue for the fourth quarter of 2008 increased to $31.2 million, compared with $19.3 million in the fourth quarter of 2007. Product revenue from the Oncotype DX(R) breast cancer assay was $30.9 million in the fourth quarter of 2008, an increase of 60 percent, compared with $19.3 million in the fourth quarter of 2007. The net loss in the fourth quarter of 2008 decreased 161 percent to $2.3 million, from $6.0 million in the fourth quarter of 2007. Basic and diluted net loss per share applicable to common stockholders was $0.08 in the fourth quarter of 2008, compared with a net loss per share of $0.21 in the fourth quarter of 2007.

Total revenue for the year ended December 31, 2008 increased to $110.6 million, compared with $64.0 million in 2007. Product revenue was $108.7 million for the year ended December 31, 2008, compared with $62.7 million in 2007. Contract revenue comprised the balance of total revenue for each of these periods. The net loss for the year ended December 31, 2008 decreased 41 percent to $16.1 million from $27.3 million in 2007. Basic and diluted net loss per share applicable to common stockholders was $0.57 for the year ended December 31, 2008, compared with a $1.02 net loss per share in 2007.

Cash and cash equivalents and short-term investments at December 31, 2008 were $56.7 million, compared with $54.4 million at September 30, 2008 and $68.4 million at December 31, 2007.

"The excellent results achieved in 2008 were fueled by the expanded clinical utility of the Oncotype DX breast cancer assay, its inclusion in clinical practice guidelines, and additional reimbursement coverage providing access to Oncotype DX for more than 90 percent of U.S. insured lives," said Kim Popovits, President and Chief Executive Officer of Genomic Health. "Looking forward, with healthcare reform a major focal point, we believe tests like Oncotype DX will continue to raise the quality of healthcare and demonstrate the economic impact of personalized medicine."

Additional Fourth Quarter and Year-End 2008 Financial Results

Approximately 50 percent of product revenue was recorded on an accrual basis and recognized at the time the test results were delivered during the fourth quarter of 2008, reflecting established payment patterns from payors with coverage policies in place.

Total operating expenses were $33.9 million in the fourth quarter of 2008, compared with $26.1 million for the fourth quarter of 2007. Included in fourth quarter 2008 operating expenses were non-cash charges of $3.8 million, including $2.4 million of stock-based compensation expense, compared with $1.9 million in the same period in 2007, and $1.4 million of depreciation and amortization expenses, compared with $1.0 million in the same period in 2007.

Total operating expenses for the year ended December 31, 2008 were $128.1 million, compared with $93.7 million for the comparable period in 2007. Included in operating expenses were non-cash charges of $14.2 million, including stock-based compensation expense of $9.2 million in the year ended December 31, 2008 compared with $6.3 million for the same period in 2007, and $5.0 million of depreciation and amortization expenses in 2008, compared with $4.0 million in the same period in 2007.

2009 Outlook and Financial Guidance

"In 2009, we intend to continue to make the necessary investments to penetrate the existing breast cancer market, broaden reimbursement to cover node-positive patients, drive international access of Oncotype DX and advance our pipeline, while continuing to move the organization toward profitability," said Brad Cole, Chief Operating and Financial Officer of Genomic Health. "To achieve these goals, we expect that the majority of our anticipated annual net loss will be realized in the first half of the year as we continue to invest in our product pipeline, U.S. sales force expansion and worldwide commercial infrastructure."

The Company is providing the following financial guidance for the full year ending December 31, 2009:

    -- Test results delivered of 50,000 to 53,000
    -- Revenue of $148 million to $160 million
    -- Net loss of $7 million to $14 million

    Recent Highlights and Accomplishments

    Commercial Progress

    -- More than 39,600 test results delivered for the full year of 2008, an
       increase of 62 percent, compared with 24,450 test results delivered in
       2007.  In the fourth quarter of 2008 more than 10,580 test results were
       delivered, an increase of 47 percent, compared with more than 7,200
       test results delivered in the same period in 2007.
    -- More than 85,000 Oncotype DX test results have been delivered as of
       December 31, 2008.
    -- In 2008, gained coverage through contracts, policies and agreements for
       an additional 56 million U.S. lives for the Oncotype DX breast cancer
       assay, bringing the total U.S. lives covered to more than 90 percent
       for appropriate node-negative breast cancer patients.
    -- Established a contract with the Blue Cross Blue Shield (BCBS)
       Association, which we believe will lead to additional coverage with
       non-contracted BCBS plans.
    -- Oncotype DX remains the only multi-gene expression assay to be
       recommended by both the National Comprehensive Cancer Network (NCCN)
       and American Society of Clinical Oncology (ASCO) in their respective
       Breast Cancer Treatment Guidelines.
    -- Continued to expand the commercial team by hiring 20 U.S. sales
       representatives in January 2009, increasing the total U.S. sales force
       to 80 sales representatives.
    -- Establishing a subsidiary in Geneva, Switzerland to support the
       company's efforts in Europe.
    -- Received test samples from 40 countries to date and have completed or
       initiated multiple international studies including ATAC and QUASAR.
    -- Continued expansion of online physician portal with enhanced real-time
       delivery of patient results to physicians and the capability for
       placing Oncotype DX orders online.

    Product Pipeline

    -- Initiated an independent clinical validation study in stage II colon
       cancer for our 18-gene Oncotype DX colon cancer assay, utilizing more
       than 1,200 patient samples from the landmark international QUASAR trial
       which examined the benefit associated with adjuvant chemotherapy.
    -- Identified patient sample cohorts for gene identification studies in
       renal and prostate cancers.
    -- Continued early development work in ductal carcinoma in situ (DCIS)
       breast cancer with the goal of initiating studies this year.

    Clinical Progress

    -- To date, 12 studies in more than 4,000 breast cancer patients have
       continued to establish the clinical utility of Oncotype DX.
    -- The National Cancer Institute has enrolled more than 5,500 patients in
       its TAILORx trial that is using the Oncotype DX breast cancer assay to
       assign treatment.
    -- In December 2008, Genomic Health and research collaborators presented
       four studies at the San Antonio Breast Cancer Symposium.  Highlights
       - An oral presentation of results from a large, contemporary study of
         breast cancer patients in Europe confirming that along with other
         standard measures such as tumor size, Oncotype DX contributes
         independently to provide a more complete picture of prognosis for
         node-negative and node-positive patients treated with aromatase
       - An oral presentation suggesting that GRB7-dependent pathways are
         potential therapeutic targets for triple-negative breast cancer, a
         subtype that does not express estrogen receptor (ER), progesterone
         receptor (PR) or HER2 genes.
       - Study results demonstrating that quantitative RT-PCR analysis is
         possible in DCIS that is adjacent to invasive ductal carcinoma of the
       - Results indicating that multiple single nucleotide polymorphisms in
         the genes that encode ER were not associated with the level of ER
         expression in breast cancer.  This suggests that differences in ER
         expression between individual tumors are likely a result of factors
         other than the inherited gene variants.

    Corporate Developments

    -- Announced management changes including naming Randy Scott as full-time
       Executive Chairman, Kimberly J. Popovits as President and Chief
       Executive Officer, and G. Bradley Cole as Chief Operating Officer and
       Chief Financial Officer.
    -- Appointed Ginger L. Graham to board of directors.

Conference Call Details

To access the live conference call today, February 3, at 4:30 p.m. Eastern Time via phone, please dial (877) 591-4951 from the United States and Canada or (719) 325-4869 internationally. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through February 10, and may be accessed by dialing (888) 203-1112 from the United States and Canada or (719) 457-0820 internationally. The replay passcode is 9067485.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's web site at Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, the Oncotype DX(R) breast cancer assay, which has been shown to predict the likelihood of chemotherapy benefit as well as the likelihood of disease recurrence in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the drivers of the company's fourth quarter and annual results; the company's beliefs regarding the ability of tests like Oncotype DX to raise the quality of healthcare and demonstrate the economic impact of personalized medicine; the company's intent to invest in its business and the areas in which it expects to make such investments; the company's intent to continue to move toward profitability; the company's expectations regarding the timing of its anticipated 2009 net loss; 2009 financial guidance, including expectations regarding the number of test results delivered, revenues, and net loss; the company's expectations regarding future reimbursement coverage with non- contracted BCBS plans and continued growth in adoption of and reimbursement of its tests; the outcome, success or results of clinical trials; the applicability of clinical study results to actual outcomes; and the company's intention to conduct additional studies in DCIS and the timing of any such studies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to compete against third parties; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the three-month period ended September 30, 2008. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

                             Genomic Health, Inc.
               Condensed Consolidated Statements of Operations
               (in thousands, except share and per share data)

                       For the Three Months Ended    For the Year Ended
                                December 31,             December 31,
                             2008         2007        2008         2007
                               (Unaudited)              (Unaudited)

    Product revenues       $30,906      $19,264     $108,658      $62,745
    Contract revenues          329           84        1,921        1,282
    Total revenues          31,235       19,348      110,579       64,027

    Cost of product
     revenues                7,310        4,915       27,185       17,331
    Research and
     development             7,957        6,015       28,624       22,053
    Selling and marketing   11,638       10,079       46,668       36,456
    General and
     administrative          6,982        5,087       25,617       17,849
    Total operating
     expenses               33,887       26,096      128,094       93,689

    Loss from operations    (2,652)      (6,748)     (17,515)     (29,662)

    Other income (expense):
    Interest and other income  326          900        1,751        3,048
    Interest expense           (69)        (143)        (386)        (678)

    Loss before income
     taxes                  (2,395)      (5,991)     (16,150)     (27,292)

    Income tax benefit          61            -           61            -

    Net loss               $(2,334)    $ (5,991)    $(16,089)    $(27,292)

    Basic and diluted net
     loss per share         $(0.08)      $(0.21)     $ (0.57)      $(1.02)

    Shares used to compute
     basic and diluted net
     loss per share     28,377,615   28,162,249   28,297,705   26,759,798

                             Genomic Health, Inc.
                    Condensed Consolidated Balance Sheets
                                (in thousands)

                                                       As of         As of
                                                     31-Dec-08     31-Dec-07
                                                    (Unaudited)    (Audited)
    Cash and cash equivalents                        $11,170        $39,164
    Short-term investments                            45,499         29,196
    Accounts receivable, net                           8,807          5,089
    Prepaid expenses and other current assets          4,782          3,105
    Total current assets                              70,258         76,554

    Property and equipment, net                       15,562         10,412
    Restricted cash                                      500            500
    Other assets                                         369            463
    Total assets                                     $86,689        $87,929

    Accounts payable                                  $1,898         $1,966
    Accrued expenses and other current liabilities    11,473          7,616
    Deferred revenue                                   3,797          1,008
    Notes payable, short-term                          1,814          2,687
    Notes payable, long-term                             225          2,039
    Other liabilities                                  1,307          1,447
    Stockholders' equity                              66,175         71,166
    Total liabilities and stockholders' equity       $86,689        $87,929

    The condensed consolidated balance sheet at December 31, 2007 has been
    derived from the audited consolidated financial statements at that date
    included in the Company's Form 10-K for the fiscal year ended December 31,

SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Enrichment of Genomic Loci for Targeted Sequencing Application Is Focus of 2009 AGBT Conference Workshop
2. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
3. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
4. Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum
5. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
6. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
7. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
8. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
9. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
10. Transgenomic Receives Accreditation From College of American Pathologists
11. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
Post Your Comments:
(Date:11/28/2015)... South Korea (PRWEB) , ... November 28, 2015 , ... ... class of eco-friendly avian, porcine and rodent control solutions , ... as peppermint and cinnamon oil, works across all sensory modalities including visual, smell, taste ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
Breaking Biology News(10 mins):